Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Nov;79(937):643–645. doi: 10.1136/pmj.79.937.643

Prostate cancer management: (2) an update on locally advanced and metastatic disease

S Bott 1, A Birtle 1, C Taylor 1, R Kirby 1
PMCID: PMC1742876  PMID: 14654575

Full Text

The Full Text of this article is available as a PDF (153.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolla M., Gonzalez D., Warde P., Dubois J. B., Mirimanoff R. O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295–300. doi: 10.1056/NEJM199707313370502. [DOI] [PubMed] [Google Scholar]
  2. Bott S. R. J., Birtle A. J., Taylor C. J., Kirby R. S. Prostate cancer management: (1) an update on localised disease. Postgrad Med J. 2003 Oct;79(936):575–580. doi: 10.1136/pmj.79.936.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crook J. M., Szumacher E., Malone S., Huan S., Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology. 1999 Mar;53(3):530–534. doi: 10.1016/s0090-4295(98)00547-0. [DOI] [PubMed] [Google Scholar]
  4. Dearnaley D. P., Bayly R. J., A'Hern R. P., Gadd J., Zivanovic M. M., Lewington V. J. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin Oncol (R Coll Radiol) 1992 Mar;4(2):101–107. doi: 10.1016/s0936-6555(05)80975-6. [DOI] [PubMed] [Google Scholar]
  5. Fosså S. D., Slee P. H., Brausi M., Horenblas S., Hall R. R., Hetherington J. W., Aaronson N., de Prijck L, Collette L. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001 Jan 1;19(1):62–71. doi: 10.1200/JCO.2001.19.1.62. [DOI] [PubMed] [Google Scholar]
  6. Hedlund P. O., Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology. 2000 Mar;55(3):328–333. doi: 10.1016/s0090-4295(99)00580-4. [DOI] [PubMed] [Google Scholar]
  7. Horwich A., Huddart R. A., Gadd J., Boyd P. J., Hetherington J. W., Whelan P., Dearnaley D. P. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol. 1998 Jan;81(1):96–99. doi: 10.1046/j.1464-410x.1998.00521.x. [DOI] [PubMed] [Google Scholar]
  8. Iversen P., Tyrrell C. J., Kaisary A. V., Anderson J. B., Van Poppel H., Tammela T. L., Chamberlain M., Carroll K., Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579–1582. [PubMed] [Google Scholar]
  9. Kaisary A. V., Tyrrell C. J., Peeling W. B., Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502–508. doi: 10.1111/j.1464-410x.1991.tb15195.x. [DOI] [PubMed] [Google Scholar]
  10. Lawton C. A., Winter K., Murray K., Machtay M., Mesic J. B., Hanks G. E., Coughlin C. T., Pilepich M. V. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937–946. doi: 10.1016/s0360-3016(00)01516-9. [DOI] [PubMed] [Google Scholar]
  11. Lipton A., Glover D., Harvey H., Grabelsky S., Zelenakas K., Macerata R., Seaman J. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol. 1994;5 (Suppl 7):S31–S35. [PubMed] [Google Scholar]
  12. Price P., Hoskin P. J., Easton D., Austin D., Palmer S. G., Yarnold J. R. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986 Aug;6(4):247–255. doi: 10.1016/s0167-8140(86)80191-8. [DOI] [PubMed] [Google Scholar]
  13. Robinson M. R., Smith P. H., Richards B., Newling D. W., de Pauw M., Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol. 1995;28(4):273–283. [PubMed] [Google Scholar]
  14. Schellhammer P. F., Kuban D. A., el-Mahdi A. M. Treatment of clinical local failure after radiation therapy for prostate carcinoma. J Urol. 1993 Dec;150(6):1851–1855. doi: 10.1016/s0022-5347(17)35913-x. [DOI] [PubMed] [Google Scholar]
  15. Small E. J., Vogelzang N. J. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 Jan;15(1):382–388. doi: 10.1200/JCO.1997.15.1.382. [DOI] [PubMed] [Google Scholar]
  16. Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., Armitage G. R., Wilson J. J., Venner P. M., Coppin C. M. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756–1764. doi: 10.1200/JCO.1996.14.6.1756. [DOI] [PubMed] [Google Scholar]
  17. Thodiyil P. A., Walsh D. C., Kakkar A. K. Thromboprophylaxis in the cancer patient. Acta Haematol. 2001;106(1-2):73–80. doi: 10.1159/000046592. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES